US7507799B2 - High affinity ligand for p75 neurotrophin receptor - Google Patents

High affinity ligand for p75 neurotrophin receptor Download PDF

Info

Publication number
US7507799B2
US7507799B2 US10/155,886 US15588602A US7507799B2 US 7507799 B2 US7507799 B2 US 7507799B2 US 15588602 A US15588602 A US 15588602A US 7507799 B2 US7507799 B2 US 7507799B2
Authority
US
United States
Prior art keywords
seq
ngf
pro
proneurotrophin
mature
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related, expires
Application number
US10/155,886
Other languages
English (en)
Other versions
US20030087804A1 (en
Inventor
Barbara L. Hempstead
Ramee Lee
Kenneth K. Teng
Pouneh Kermani
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cornell Research Foundation Inc
Original Assignee
Cornell Research Foundation Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cornell Research Foundation Inc filed Critical Cornell Research Foundation Inc
Priority to US10/155,886 priority Critical patent/US7507799B2/en
Assigned to CORNELL RESEARCH FOUNDATION, INC. reassignment CORNELL RESEARCH FOUNDATION, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: HEMPSTEAD, BARBARA L., KERMANI, POUNEH, LEE, RAMEE, TENG, KENNETH K.
Publication of US20030087804A1 publication Critical patent/US20030087804A1/en
Priority to US11/881,763 priority patent/US8034347B2/en
Assigned to NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT reassignment NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT EXECUTIVE ORDER 9424, CONFIRMATORY LICENSE Assignors: CORNELL UNIVERSITY
Application granted granted Critical
Publication of US7507799B2 publication Critical patent/US7507799B2/en
Expired - Fee Related legal-status Critical Current
Adjusted expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/484—Plasmin (3.4.21.7)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
US10/155,886 2001-05-25 2002-05-24 High affinity ligand for p75 neurotrophin receptor Expired - Fee Related US7507799B2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US10/155,886 US7507799B2 (en) 2001-05-25 2002-05-24 High affinity ligand for p75 neurotrophin receptor
US11/881,763 US8034347B2 (en) 2001-05-25 2007-07-27 Method for inhibiting apoptosis through the p75 neurotrophin receptor

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US29382301P 2001-05-25 2001-05-25
US30551001P 2001-07-13 2001-07-13
US10/155,886 US7507799B2 (en) 2001-05-25 2002-05-24 High affinity ligand for p75 neurotrophin receptor

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/881,763 Continuation US8034347B2 (en) 2001-05-25 2007-07-27 Method for inhibiting apoptosis through the p75 neurotrophin receptor

Publications (2)

Publication Number Publication Date
US20030087804A1 US20030087804A1 (en) 2003-05-08
US7507799B2 true US7507799B2 (en) 2009-03-24

Family

ID=26968166

Family Applications (2)

Application Number Title Priority Date Filing Date
US10/155,886 Expired - Fee Related US7507799B2 (en) 2001-05-25 2002-05-24 High affinity ligand for p75 neurotrophin receptor
US11/881,763 Expired - Fee Related US8034347B2 (en) 2001-05-25 2007-07-27 Method for inhibiting apoptosis through the p75 neurotrophin receptor

Family Applications After (1)

Application Number Title Priority Date Filing Date
US11/881,763 Expired - Fee Related US8034347B2 (en) 2001-05-25 2007-07-27 Method for inhibiting apoptosis through the p75 neurotrophin receptor

Country Status (7)

Country Link
US (2) US7507799B2 (de)
EP (1) EP1575477B1 (de)
AT (1) ATE554784T1 (de)
AU (1) AU2002259305A1 (de)
CA (1) CA2447986A1 (de)
DK (1) DK1575477T3 (de)
WO (1) WO2002096356A2 (de)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080025978A1 (en) * 2001-05-25 2008-01-31 Cornell Research Foundation Inc. High affinity ligand for p75 neurotrophin receptor
US20080050776A1 (en) * 2006-05-26 2008-02-28 Kenneth Neet Stable mutated pro nerve growth factors
US20140256638A1 (en) * 2013-02-14 2014-09-11 The Regents Of The University Of California Peptoid neutralizing agents
WO2015038582A3 (en) * 2013-09-11 2015-06-11 New York University Methods and compositions for treating bone diseases
US10308694B2 (en) 2011-12-19 2019-06-04 Wacker Chemie Ag ProNGF mutants and uses thereof in the production of beta-NGF

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8066997B2 (en) 2002-12-20 2011-11-29 Anders Nykjaer Modulation of activity of neurotrophins
DE10317369A1 (de) * 2003-04-15 2004-11-11 Scil Proteins Gmbh proNGF als pharmazeutisch wirksames Mittel zur Behandlung demyelinisierender Erkrankungen
EP1500399A1 (de) * 2003-07-24 2005-01-26 Institut Pasteur Aktive und passive Immunisierung gegen pro-apoptotischen Neurotrophinen zur Behandlung oder Vorbeugung von neurologischen Krankheiten
US20060239966A1 (en) * 2003-10-20 2006-10-26 Tornoee Jens In vivo gene therapy of parkinson's disease
WO2005044293A2 (en) * 2003-11-07 2005-05-19 Lay Line Genomics S.P.A. Compositions able to prevent neurodegenerative processes and methods of assaying the same
ITRM20030601A1 (it) 2003-12-24 2005-06-25 Lay Line Genomics Spa Metodo per l'umanizzazione di anticorpi e anticorpi umanizzati con esso ottenuti.
ITRM20050045A1 (it) * 2005-02-02 2006-08-03 Consiglio Nazionale Ricerche Proteina isolata da eisenia foetida simile all'ngf umano e usi relativi.
ITRM20050290A1 (it) 2005-06-07 2006-12-08 Lay Line Genomics Spa Uso di molecole in grado di inibire il legame tra ngf e il suo recettore trka come analgesici ad effetto prolungato.
LT3225251T (lt) 2006-12-21 2020-04-10 H. Lundbeck A/S Proneurotrofinų veiklos moduliavimas
JP5871249B2 (ja) * 2010-05-31 2016-03-01 国立研究開発法人産業技術総合研究所 成長因子のプロペプチド
CN103228295B (zh) * 2010-06-15 2015-06-24 康奈尔大学 一种限制急性心肌缺血后微血管损伤的方法
WO2012068332A2 (en) * 2010-11-17 2012-05-24 Cornell University Methods for treating early stage or mild neurological disorders
US9078878B2 (en) 2010-12-01 2015-07-14 Alderbio Holdings Llc Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75
JP6190723B2 (ja) 2010-12-01 2017-08-30 アルダーバイオ ホールディングス エルエルシー 抗ｎｇｆ組成物およびその使用
US9067988B2 (en) 2010-12-01 2015-06-30 Alderbio Holdings Llc Methods of preventing or treating pain using anti-NGF antibodies
US11214610B2 (en) 2010-12-01 2022-01-04 H. Lundbeck A/S High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris
US9884909B2 (en) 2010-12-01 2018-02-06 Alderbio Holdings Llc Anti-NGF compositions and use thereof
US9539324B2 (en) 2010-12-01 2017-01-10 Alderbio Holdings, Llc Methods of preventing inflammation and treating pain using anti-NGF compositions
RU2486918C1 (ru) * 2011-10-25 2013-07-10 Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Московский государственный университет имени М.В. Ломоносова" (МГУ) Способ стимулирования восстановления периферической иннервации тканей с помощью векторных конструкций
CN104774264B (zh) * 2014-01-15 2018-09-14 上海易乐生物技术有限公司 抗人proBDNF单克隆抗体及其在疼痛中的作用
EP3265493B1 (de) 2015-03-02 2024-01-10 180 Therapeutics LP Verfahren zur behandlung einer lokalisierten fibrotischen erkrankung unter verwendung eines il-33-antagonisten
WO2019162942A1 (en) * 2018-02-20 2019-08-29 Carmel Haifa University Economic Corporation Ltd. Compositions and methods for delivery and expression of small inhibitory peptides and use thereof
IT202000007720A1 (it) * 2020-04-10 2021-10-10 Alessandra Marconi Peptidi e loro usi
IT202000032423A1 (it) * 2020-12-24 2022-06-24 Univ Degli Studi Di Trieste Metodo per la produzione di forme processate proteoliticamente di fattori trofici o fattori di crescita
WO2022226170A1 (en) * 2021-04-22 2022-10-27 Cornell University The immunomodulatory ligand b7-1 mediates synaptic remodeling by p75ntr

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5169764A (en) 1990-08-08 1992-12-08 Regeneron Pharmaceuticals, Inc. Multitrophic and multifunctional chimeric neurotrophic factors, and nucleic acids and plasmids encoding the chimeras
US5288622A (en) * 1983-03-03 1994-02-22 Genentech, Inc. Human nerve growth factor by recombinant technology
WO1997036607A1 (en) 1996-03-29 1997-10-09 The Regents Of The University Of California Synthetic peptide derivatives with nerve growth factor-like neurotrophic activity
WO2000024415A2 (en) 1998-10-28 2000-05-04 Cornell Research Foundation, Inc. Methods for regulating angiogenesis and vascular integrity using trk receptor ligands
US6077829A (en) 1996-05-27 2000-06-20 Regeneron Pharmaceuticals, Inc. Stable pharmaceutical composition of BDNF
US6172086B1 (en) 1996-11-13 2001-01-09 Vertex Pharmaceuticals Incorporated Methods and compositions for stimulating neurite growth
WO2001052843A1 (en) 2000-01-18 2001-07-26 Mcgill University β-TURN PEPTIDOMIMETIC CYCLIC COMPOUNDS
WO2001075278A1 (en) 2000-03-31 2001-10-11 Innogy Plc Passive valve assembly

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6960440B2 (en) * 1999-06-07 2005-11-01 The Trustes of Columbia University in the City of New York Methods for screening for apoptosis modulators using NADE, p75NTR-associated cell death executor
EP1575477B1 (de) * 2001-05-25 2012-04-25 Cornell Research Foundation, Inc. HOCHAFFINER LIGAND FÜR p75 NEUROTROPHIN-REZEPTOR

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5288622A (en) * 1983-03-03 1994-02-22 Genentech, Inc. Human nerve growth factor by recombinant technology
US5169764A (en) 1990-08-08 1992-12-08 Regeneron Pharmaceuticals, Inc. Multitrophic and multifunctional chimeric neurotrophic factors, and nucleic acids and plasmids encoding the chimeras
WO1997036607A1 (en) 1996-03-29 1997-10-09 The Regents Of The University Of California Synthetic peptide derivatives with nerve growth factor-like neurotrophic activity
US6077829A (en) 1996-05-27 2000-06-20 Regeneron Pharmaceuticals, Inc. Stable pharmaceutical composition of BDNF
US6172086B1 (en) 1996-11-13 2001-01-09 Vertex Pharmaceuticals Incorporated Methods and compositions for stimulating neurite growth
WO2000024415A2 (en) 1998-10-28 2000-05-04 Cornell Research Foundation, Inc. Methods for regulating angiogenesis and vascular integrity using trk receptor ligands
WO2001052843A1 (en) 2000-01-18 2001-07-26 Mcgill University β-TURN PEPTIDOMIMETIC CYCLIC COMPOUNDS
WO2001075278A1 (en) 2000-03-31 2001-10-11 Innogy Plc Passive valve assembly

Non-Patent Citations (30)

* Cited by examiner, † Cited by third party
Title
Akinaga, et al., "Antitumor effect of KT6124, a novel derivative of protein kinase inhibitor K-252a, and its mechanism of action", Cancer Chemother Pharmacol 1992, 29: 266-272.
Barker, et al. ,"p75NTR Is Positively Promiscuous: Novel Partners and New Insights", Neuron 2004, 42:529-533.
Botchkarev, et al., "A role for p75 neurotrophin receptor in the control of apoptosis-driven hair follicle regression", The FASEB Journal 2000, 14:1931-1942.
Brann, et al., "Ceramide Signaling Downstream of the P75 Neurotrophin Receptor Mediates the Effects of Nerve Growth Factor on Outgrowth of Cultured Hippocampal Neurons", J. Neurosci 1999, 19(19):8199-8206.
Chao, et al., "Neurotrophins: To Cleave or Not to Cleave", Neuron 2002, 33:9-12.
Chen, et al., "Characterization of nerve growth factor precursor protein expression in rat round spermatids and the trophic effects of nerve growth factor in the maintenance of Sertoli cell viability", Molecular and Cellular Endocrinology 1997, 127:129-136.
Cortazzo, MH, et al., "Nerve Growth Factor (NGF)-Mediated Protection of Neural Crest Cells from Antimitotic Agent-Induced Apoptosis: the Role of the Low Affinity NGF Receptor", The Journal of Neuroscience, vol. 16, No. 2, pp. 3895-3899; Jun. 15, 1996.
Delsite, et al., "Characterization of Nerve Growth Factor Precursor Protein Expression by Human Prostate Stromal Cells: A Role in Selective Neurotrophin Stimulation of Prostate Epithelial Cell Growth", The Prostate 1999, 41:39-48.
Drinkwater, et al., "The Carboxyl Terminus of Nerve Growth Factor is Required for Biological Activity", The Journal of Biological Chemistry 1993, 268(31):23202-23207.
Evans, et al., "Antitumor Activity of CEP-751 (KT-6587) on Human Neuroblastoma and Medulloblastoma Xenografts", Clin. Cancer Res. 1999, 5(11():3594-3602.
Fahnestock, et al., "The Precursor Pro-Nerve Growth Factor Is the Predominant Form of Nerve Growth Factor in Brain and Is Increased in Alzheimer's Disease", Molecular and Cellular Neuroscience 2001, 18:210-220.
Fotouhi, et al., "Potent Peptide Inhibitors of Stromelysin Based on the Prodomain Region of Matrix Metalloproteinases", The Journal of Biological Chemistry 1994, 269(48):30227-30231.
Frade, et al., "Induction of cell death by endogenous nerve growth factor through its p75 receptor", Letters to Nature 1996, 383(6596):166-168.
Gentry JJ. et al.; "Nerve Growth Factor Activation of Nuclear Factor .kapp.B through Its p. 75 Receptor Is an Anti-apoptotic Signal in RN22 Schwannoma Cells", The Journal of Biological Chemistry, vol. 275, No. 11, pp. 7558-7565; Mar. 17, 2000.
Heymach, Jr., et al., "The Biosynthesis of Neurotrophin Heterodimers by Transfected Mammalian Cells", The Journal of Biological Chemistry 1995, 270(20):12297-12304.
Heymach, Jr., et al., "The Regulated Secretion and Vectorial Targeting of Neurotrophins in Neuroendocrine and Epithelial Cells", The Journal of Biological Chemistry 1996, 271(41):25430-25437.
Kolbeck, et al., "Characterisation of neurotrophin dimers and monomers", Eur. J. Biochem. 1994, 225:995-1003.
Lee, et al., "Regulation of Cell Survival by Secreted Proneurotrophins", Science 2001, 294:1945-1948.
Mizushima, et al., "Antitumor Therapeutic Effect of Neurotropin on Transplanted Tumors in Rates", Oncology 1984, 41:289-292.
Mowla, et al., "Biosynthesis and Post-translational Processing of the Precursor to Brain-derived Neurotrophic Factor", The Journal of Biological Chemistry 2001, 276(16):12660-12666.
Nykjaer A. et al., "Sortilin is Essential for proNGF-induced Neuronal Cell Death", Natyer, vol. 427, pp. 843-848; Feb. 26, 2004. (Abstract).
Rattenholl, et al., "Pro-Sequence Assisted Folding and Disulfide Bond Formation of Human Nerve Growth Factor", J. Mol. Biol. 2001, 305:523-533.
Reinshagen, et al., "Commercial mouse and human nerve growth factors contain nerve growth factor prohormone isoforms", Journal of Neuroscience Methods 1997, 76(1):75-81.
Rowinsky, et al., "Phase I and Pharmacologic Study of the Specific Matrix Metalloproteinase Inhibitor BAY 12-9566 on a Protracted Oral Daily Dosing Schedule in Patients With Solid Malignancies", Journal of Clinical Oncology 2000, 18(1):178-186.
Seidah, et al., "Cellular processing of the neurotrophin precursors of NT3 and BDNF by the mammalian proprotein convertases", FEBS Letters 1996, 379:247-250.
Soilu-Haenninen M. et al., "Nerve Growth Factor Signaling Through p. 75 induces apoptosis in Schwann cells via a Bcl-2-independent pathway", Journal of Neuroscience, vol. 19, No. 12, pp. 4828-4838; Jun. 15, 1999.
Suter, et al., "NGF/BDNF Chimeric Proteins: Analysis of Neurotrophin Specificity by Homolog-scanning Mutagenesis", The Journal of Neuroscience 1992, 12(1):306-318.
Suter, et al., "Two conserved domains in the NGF propeptide are necessary and sufficient for the biosynthesis of correctly processed and biologically active NGF", The EMBO Journal 1991, 10(9):2395-2400.
Wang, et al., "p75NTR Mediates Neurotrophin-Induced Apoptosis of Vascular Smooth Muscle Cells", American Journal of Pathology 2000, 157(4):1247-1258.
Yardley, et al., "Expression of nerve growth factor mRNA and its translation products in the anagen hair follicle", Experimental Dermatology 2000, 9:283-289.

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080025978A1 (en) * 2001-05-25 2008-01-31 Cornell Research Foundation Inc. High affinity ligand for p75 neurotrophin receptor
US8034347B2 (en) 2001-05-25 2011-10-11 Cornell Research Foundation, Inc. Method for inhibiting apoptosis through the p75 neurotrophin receptor
US20080050776A1 (en) * 2006-05-26 2008-02-28 Kenneth Neet Stable mutated pro nerve growth factors
US10308694B2 (en) 2011-12-19 2019-06-04 Wacker Chemie Ag ProNGF mutants and uses thereof in the production of beta-NGF
US20140256638A1 (en) * 2013-02-14 2014-09-11 The Regents Of The University Of California Peptoid neutralizing agents
WO2015038582A3 (en) * 2013-09-11 2015-06-11 New York University Methods and compositions for treating bone diseases

Also Published As

Publication number Publication date
EP1575477B1 (de) 2012-04-25
US8034347B2 (en) 2011-10-11
ATE554784T1 (de) 2012-05-15
EP1575477A2 (de) 2005-09-21
AU2002259305A8 (en) 2006-11-02
US20080025978A1 (en) 2008-01-31
US20030087804A1 (en) 2003-05-08
DK1575477T3 (da) 2012-07-23
AU2002259305A1 (en) 2002-12-09
CA2447986A1 (en) 2002-12-05
EP1575477A4 (de) 2006-11-08
WO2002096356A3 (en) 2006-05-18
WO2002096356A2 (en) 2002-12-05

Similar Documents

Publication Publication Date Title
US8034347B2 (en) Method for inhibiting apoptosis through the p75 neurotrophin receptor
RU2146262C1 (ru) Пептиды, способ их получения, фармацевтическая композиция и способ ее получения
US20050260616A1 (en) Nucleotide and protein sequences of Nogo genes and methods based thereon
JP2006507356A (ja) ミオスタチンのメタロプロテアーゼ活性化およびミオスタチン活性の調節方法
US20120196803A1 (en) Fusion proteins for delivery of gdnf and bdnf to the central nervous system
Wilk et al. Glutamyl aminopeptidase (aminopeptidase A), the BP-1/6C3 antigen
JP2002530431A (ja) ＴＧＦβ１−インヒビターペプチド
JP2010138179A (ja) Ａｃｔｒｉｉｂ融合ポリペプチドおよびその使用
PL207202B1 (pl) Modyfikowany propeptyd GDF-8 i jego zastosowanie, kodująca go cząsteczka kwasu nukleinowego, kompozycja farmaceutyczna, rekombinowana komórka oraz sposób wytwarzania modyfikowanego propeptydu GDF-8
MX2008007324A (es) Usos de antagonistas de miostatina.
JP2002539076A (ja) 新脈管形成抑制のための方法および組成物
JPH11508886A (ja) ミエリン会合糖タンパク質（ｍａｇ）およびそのインヒビターを用いた組成物および方法
JP4067117B2 (ja) 選択性スロンビン抑制剤としてのブラジキニン同族体
US20020054870A1 (en) Peptide from soluble form of acetylcholinesterase, active as a calcium channel modulator
US7772204B1 (en) Perlecan and growth factor for wound and cutaneous injury healing
WO2000067771A1 (en) Antiangiogenic endostatin peptides, endostatin variants and methods of use
US20080125352A1 (en) Unique Integrin Binding Site in Connective Tissue Growth Factor
US5578566A (en) KGF receptor-derived antagonists of KGF binding
AU8501198A (en) Methods and compositions for regulating nuclear trafficking of proteins
US20050148508A1 (en) Pigment epithelium derived factor from human plasma and methods of use thereof
KR20180099092A (ko) β1 인테그린 신호전달 억제 활성을 갖는 펩타이드 및 이를 포함하는 약학 조성물
WO1993021945A1 (en) METHODS FOR TREATING VASCULAR DISORDERS BY INHIBITING THE ENDOTHELIN STIMULATORY ACTIVITY OF TGF$g(b)
US7446095B2 (en) Peptides modulating caspase activation
KR100568755B1 (ko) Ｙｈ 모티프를 포함하는 펩타이드를 유효성분으로함유하는 혈관신생 억제제
US6329500B1 (en) Transforming growth factor-β binding site

Legal Events

Date Code Title Description
AS Assignment

Owner name: CORNELL RESEARCH FOUNDATION, INC., NEW YORK

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:HEMPSTEAD, BARBARA L.;LEE, RAMEE;TENG, KENNETH K.;AND OTHERS;REEL/FRAME:013165/0662

Effective date: 20020715

FEPP Fee payment procedure

Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

AS Assignment

Owner name: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF

Free format text: EXECUTIVE ORDER 9424, CONFIRMATORY LICENSE;ASSIGNOR:CORNELL UNIVERSITY;REEL/FRAME:021434/0308

Effective date: 20020731

STCF Information on status: patent grant

Free format text: PATENTED CASE

FPAY Fee payment

Year of fee payment: 4

SULP Surcharge for late payment
FPAY Fee payment

Year of fee payment: 8

FEPP Fee payment procedure

Free format text: PAT HOLDER NO LONGER CLAIMS SMALL ENTITY STATUS, ENTITY STATUS SET TO UNDISCOUNTED (ORIGINAL EVENT CODE: STOL); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

FEPP Fee payment procedure

Free format text: MAINTENANCE FEE REMINDER MAILED (ORIGINAL EVENT CODE: REM.); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

LAPS Lapse for failure to pay maintenance fees

Free format text: PATENT EXPIRED FOR FAILURE TO PAY MAINTENANCE FEES (ORIGINAL EVENT CODE: EXP.); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

STCH Information on status: patent discontinuation

Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362

FP Lapsed due to failure to pay maintenance fee

Effective date: 20210324